Drugs / Cobomarsen
Cobomarsen
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02580552 | Feb 2016 → Oct 2020 | B-cell chronic lymphocytic leukemia, adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma activated B-cell type, mycosis fungoides | miRagen Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT03837457 | Oct 2019 → Jul 2020 | mycosis fungoides | miRagen Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03713320 | Apr 2019 → Oct 2020 | mycosis fungoides | miRagen Therapeutics, Inc. | Terminated | Missed primary Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cobomarsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03837457 ↗ |
| Known as | M-11667 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989993 ↗ |
| Known as | M11667 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989993 ↗ |
| Known as | MRG-106 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989993 ↗ |
| Known as | MRG-106 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989993 ↗ |
| Action | Inhibit | “Cobomarsen is an inhibitor of a molecule called miR-155” NCT02580552 ↗ |
| Route | Intravenous | “Cobomarsen will be administered in the clinic by 2-hr intravenous infusion” NCT03713320 ↗ |